SLC22A1

Solute carrier family 22 member 1 · O15245 · SLC22A1 on Sugi Atlas →

103,296 patent compounds predicted against SLC22A1, 79,260 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tetrabuthylammonium (SCHEMBL22384)	1.00	4/20
Norlevorphanol (SCHEMBL23822)	1.00	4/20
Norlevorphanol (SCHEMBL23823)	1.00	4/20
Imipramine (SCHEMBL34282)	1.00	4/20
Trimipramine (SCHEMBL35144)	1.00	4/20
Imipramine (SCHEMBL41765)	0.97	4/20
Imipramine (SCHEMBL41766)	0.97	4/20
Tetrabuthylammonium (SCHEMBL466)	0.92	4/20
Tetrabuthylammonium (SCHEMBL1891)	0.92	4/20
Tetrabuthylammonium (SCHEMBL9117)	0.92	4/20
Tetrabuthylammonium (SCHEMBL21980)	0.92	4/20
Tetrabuthylammonium (SCHEMBL24883)	0.92	4/20
Tetrabuthylammonium (SCHEMBL37661)	0.92	4/20
Tetrabuthylammonium (SCHEMBL37663)	0.92	4/20
Tetrapropylammonium (SCHEMBL49582)	0.91	4/20
Tetrabuthylammonium (SCHEMBL21975)	0.86	4/20
Tetrabuthylammonium (SCHEMBL15098)	0.75	4/20
Tetrabuthylammonium (SCHEMBL35671)	0.75	4/20
Tetrabuthylammonium (SCHEMBL49814)	0.71	4/20
Tetrabuthylammonium (SCHEMBL2215)	0.67	4/20

Clinical trials — most relevant to SLC22A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome	PHASE2	RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Autonomic Function in Patients With COPD	nan	COMPLETED
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population	nan	COMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders	nan	UNKNOWN
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC22A1 binder may also engage these)

Protein	Name	Similarity
O08966	—	1.000	O08966 →
O02713	—	1.000	O02713 →
Q863T6	—	1.000	Q863T6 →
O77504	—	1.000	O77504 →
Q8MJI6	—	1.000	Q8MJI6 →
A7MBE0	—	0.998	A7MBE0 →
Q9R0W2	—	0.997	Q9R0W2 →
Q63089	—	0.996	Q63089 →
Q5R5H7	—	0.994	Q5R5H7 →
O76082	—	0.994	O76082 →
O88446	—	0.993	O88446 →
SLC22A2	Solute carrier family 22 member 2	0.992	landscape →
Q9Y226	—	0.992	Q9Y226 →
Q9WTW5	—	0.992	Q9WTW5 →
O70577	—	0.991	O70577 →
A9CB25	—	0.990	A9CB25 →
Q9R141	—	0.990	Q9R141 →
SLC22A4	Solute carrier family 22 member 4	0.990	landscape →
SLC22A3	Solute carrier family 22 member 3	0.989	landscape →
Q9Z0E8	—	0.989	Q9Z0E8 →
Q9Z306	—	0.988	Q9Z306 →
O70594	—	0.987	O70594 →
Q91WU2	—	0.985	Q91WU2 →
A6QLW8	—	0.985	A6QLW8 →
O57379	—	0.985	O57379 →
B2GV36	—	0.985	B2GV36 →
Q6A4L0	—	0.984	Q6A4L0 →
O35956	—	0.984	O35956 →
Q9WTN6	—	0.983	Q9WTN6 →
Q8HY24	—	0.982	Q8HY24 →